Telehealth Narcolepsy Prescribing: What Psychiatrists Can Do in Michigan

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients via telehealth, you’re probably wondering: Can I actually prescribe stimulants remotely? What are the state restrictions? How does my scope compare to other providers?

The short answer: Yes, you can manage narcolepsy through telehealth—but the devil’s in the details. Federal allowances through 2025 make it possible to prescribe Schedule II stimulants like Adderall without an initial in-person visit, but state laws add layers of complexity. Psychiatrists have full prescriptive authority everywhere, while PMHNPs face varying restrictions depending on where they practice.

Here’s what you actually need to know to treat narcolepsy patients compliantly and profitably.

Why Narcolepsy Management is Different (and Why It Matters)

Narcolepsy isn’t your typical psychiatric case. It’s a rare neurological disorder affecting roughly 1 in 2,000 Americans—about 160,000 people total. Most psychiatrists will see only a handful of narcolepsy patients in their career, which creates both a challenge and an opportunity.

The clinical challenge: Unlike depression or anxiety, narcolepsy diagnosis requires objective testing—typically polysomnography with a Multiple Sleep Latency Test (MSLT). Most psychiatrists don’t perform these tests; they rely on sleep specialists for diagnosis confirmation. This means coordination of care is critical, even in telehealth settings.

The prescribing challenge: First-line narcolepsy treatment is stimulant therapy—Schedule II medications like methylphenidate, dextroamphetamine, or amphetamine salts (Adderall). You’re also looking at Schedule IV wakefulness promoters like modafinil, and occasionally controlled sedatives like sodium oxybate (a Schedule III narcotic with its own REMS program).

This creates intensive compliance requirements:

• Monthly prescriptions (Schedule II = no refills)
• Mandatory PDMP checks in nearly all states
• Higher doses than typical ADHD treatment
• Frequent follow-ups for dose optimization
• Prior authorization battles with insurance

The opportunity: Narcolepsy patients are desperately underserved. With sleep specialists concentrated in urban areas and many unwilling to take new patients, telehealth psychiatrists who understand narcolepsy management can fill a genuine care gap. These are typically long-term, stable patients who need ongoing medication management—predictable revenue with minimal therapy time required.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Federal Telehealth Rules: The 2025 Extension and What Comes Next

Here’s the regulatory landscape as of 2026:

The DEA waiver remains in effect through December 2025. This pandemic-era flexibility suspends the Ryan Haight Act’s in-person examination requirement, meaning you can initiate Schedule II-V controlled substances via telehealth without ever meeting the patient face-to-face. The DEA and HHS extended this policy in November 2024, buying providers at least through end of year 2025 to operate under these rules.

What this means practically:

• You can diagnose narcolepsy (or confirm existing diagnosis) via video
• You can prescribe Adderall, Ritalin, or other Schedule II stimulants in the initial visit
• You can manage ongoing treatment entirely through telehealth

The catch: This flexibility could change after 2025. The DEA proposed new permanent telemedicine registration rules that might require either an initial in-person exam within 30 days or special DEA telehealth certification. Stay current on these developments—what works today might need adjustment in 2026.

Best practice now: Treat the waiver as temporary. Document thoroughly, establish robust telehealth standards of care, and prepare contingency plans (like partnerships with local physicians for potential in-person exams) in case regulations tighten.

What Psychiatrists Can Do: Full Authority, Maximum Flexibility

As an MD or DO, you have unrestricted prescriptive authority for narcolepsy in every state. Here’s your scope:

Clinical capabilities:

• Full diagnostic authority (can order labs, coordinate sleep studies)
• Prescribe all narcolepsy medications without restriction:
• Schedule II stimulants (amphetamines, methylphenidate)
• Schedule IV wakefulness agents (modafinil, armodafinil)
• Off-label agents (SSRIs for cataplexy, tricyclics)
• Sodium oxybate (requires REMS enrollment)
• Adjust doses via virtual follow-ups
• Manage comorbid conditions (depression, anxiety, ADHD)

Telehealth workflow:

1. Initial evaluation (30-45 min): Verify narcolepsy diagnosis, review sleep study results, assess current symptoms
2. Medication initiation: Start with first-line agent (typically modafinil or amphetamine), e-prescribe via EPCS
3. Follow-up schedule: Week 2-4 (dose adjustment), then monthly during titration, then every 3 months when stable
4. PDMP checks: Before every controlled substance prescription (state-mandated in most jurisdictions)
5. Documentation: Maintain standard of care equivalent to in-person (symptom scales, side effect monitoring, sleep diary review)

State-specific limitations for psychiatrists are rare but exist:

• Florida: State law prohibits telehealth prescribing of Schedule II except for psychiatric disorders, inpatient care, or hospice. Since narcolepsy isn’t psychiatric, technically you’d need one in-person visit. However, if the patient also has ADHD (common comorbidity), you might prescribe under psychiatric treatment exception. Gray area—proceed cautiously.
• Most other states: No physician-specific telehealth barriers beyond federal requirements

The bottom line: As a psychiatrist, you can fully manage narcolepsy via telehealth in 45+ states with minimal regulatory friction. Your main concerns are staying licensed in patient states and following standard controlled-substance protocols.

PMHNP Prescribing Authority: The State-by-State Reality

Nurse practitioners face a patchwork of state laws that significantly impact narcolepsy management. Here’s the breakdown:

Full Practice States (PMHNPs Function Like Psychiatrists)

California (with caveats):

• Current situation: NPs need physician protocols until they achieve ‘104 NP’ status
• Timeline: AB 890 created a transition—NPs work as ‘103 NPs’ in group settings (2023+), then can apply for full independence after 3 years/4,600 hours (earliest: 2026)
• Narcolepsy implications: By 2026, experienced CA PMHNPs can independently prescribe all narcolepsy meds. Until then, need standardized procedure agreement covering Schedule II prescribing
• Telehealth: Fully permitted; no additional restrictions

New York:

• Authority: Full independence after 3,600 hours (roughly 2 years) of collaborative practice
• Prescribing: Experienced NPs prescribe Schedule II-V without physician oversight
• Narcolepsy management: After hitting 3,600 hours, a PMHNP can manage narcolepsy identically to a psychiatrist
• New NPs: Still need written collaborative agreement until experience threshold met
• Telehealth: Strong parity laws; no barriers to virtual controlled-substance prescribing

Illinois:

• Full Practice Authority: After 4,000 hours + 250 hours pharmacology CE
• Unique rules: FPA NPs must have physician consultation relationship for Schedule II opioids (monthly review required) and benzodiazepines >120 days. Stimulants are NOT included.
• Narcolepsy sweet spot: IL PMHNPs with FPA can independently prescribe Adderall, modafinil, and all narcolepsy meds without mandated physician consultation
• Telehealth: Excellent parity laws, no special restrictions

Restricted Practice States (PMHNPs Need Physician Collaboration)

Texas (most restrictive):

• Hard stop: NPs cannot prescribe Schedule II in outpatient settings except hospital inpatient or hospice care
• What this means: A Texas PMHNP cannot write Adderall prescriptions for narcolepsy patients in telehealth or clinic
• Workaround: Use modafinil (Schedule IV, which NPs can prescribe) or have collaborating physician write stimulant prescriptions
• Collaboration required: All TX NPs need Prescriptive Authority Agreement with supervising physician
• Telehealth: Permitted, but scope limitations remain

Florida (complex):

• Supervision: PMHNPs must have collaborative agreement (not eligible for autonomous practice)
• 7-day limit: NPs can prescribe Schedule II for maximum 7-day supply (unless certified ‘psychiatric nurse’ prescribing psychiatric meds)
• Narcolepsy problem: Since narcolepsy isn’t psychiatric, technically limited to weekly prescriptions—completely impractical
• Practical solution: Have collaborating psychiatrist prescribe stimulants, or use Schedule IV alternatives
• State telehealth restriction: Florida law prohibits telehealth Schedule II prescribing except for psychiatric treatment, inpatient, or hospice—adds another barrier

Pennsylvania:

• Collaborative agreement required: All CRNPs need physician collaboration
• Quantity limits: 30-day maximum for Schedule II, 90 days for Schedule III-IV
• Practical impact: Monthly prescribing aligns with best practice anyway, so less burdensome than Florida
• Telehealth: Permitted with standard collaborative oversight

State-by-State Comparison Table

The Economics of Narcolepsy Management: What You Actually Make

Let’s talk numbers—because that’s what matters when you’re deciding whether to add narcolepsy patients to your panel.

Patient acquisition reality check:

Forget any claims about acquiring psychiatric patients for ‘$30-50’ through DIY marketing—that’s fiction. Here’s the actual cost breakdown when providers try to build their own patient flow:

• Google Ads for mental health: $15-40+ per click, with most clicks not converting to booked patients. Realistic cost per booked patient: $200-400+
• SEO investment: 6-12 months of consistent spending before meaningful results, typically $2,000-4,000/month for quality work
• Directory listings (Psychology Today, Zocdoc): Monthly fees + per-booking charges. Zocdoc charges $35-100+ per booking, plus monthly subscription
• All-in DIY marketing cost: $3,000-5,000/month with uncertain ROI, especially in the first 6-12 months

The platform alternative: Pay-per-appointment models (like Klarity’s approach) eliminate upfront risk. You pay a standard listing fee only when a pre-qualified patient books with you. No wasted ad spend, no monthly retainers, no gambling on which marketing channel might work.

Narcolepsy patient economics:

Typical reimbursement:

• Initial evaluation (99214 or 99204): $120-180
• Follow-up med checks (99213/99214): $80-130 per visit
• Frequency: Monthly during titration (3-6 months), then quarterly when stable

Annual revenue per patient: $1,000-1,500 (insurance), or $1,200-2,000 (cash-pay at $100-150/visit)

Volume potential: With efficient 15-20 minute follow-ups, you can see 3-4 narcolepsy patients per hour in medication management mode. Ten established narcolepsy patients = 3-4 hours of work per month, generating $2,500-4,000 in billings.

Insurance vs. cash-pay:

Insurance reimbursement comes with headaches:

• Prior authorizations (30-60 minutes of admin work per patient)
• Lower effective rates (mental health providers paid 22% less than other specialists by private insurance)
• Delayed payments

Cash-pay advantages:

• Predictable revenue (collected at time of service)
• No authorization battles
• Many narcolepsy patients willing to pay out-of-pocket due to treatment scarcity

Medicare considerations: If treating Medicare patients, remember that PMHNPs are reimbursed at 85% of physician rates for services billed under their own NPI. For collaborative practices, ‘incident-to’ billing at 100% requires physician oversight and historically isn’t compatible with pure telehealth.

The Klarity value proposition: Instead of spending thousands per month hoping to attract the right patients, you get matched with pre-qualified narcolepsy patients who’ve already been screened for your specialty and availability. You control your schedule, accept only the patients who fit, and pay only when appointments actually happen. For most providers—especially those starting out or scaling—that’s guaranteed ROI versus gambling on marketing channels.

Medication Management Workflow: Making It Efficient and Compliant

Narcolepsy medication management is straightforward once you have systems in place. Here’s a proven workflow:

Initial Evaluation (30-45 minutes):

• Confirm diagnosis: Review sleep study results (PSG + MSLT), typically uploaded by patient
• Rule out mimickers: Screen for sleep apnea, depression, medication side effects
• Assess severity: Epworth Sleepiness Scale, frequency of sleep attacks, presence of cataplexy
• Document: ICD-10 G47.4xx codes for narcolepsy type
• Treatment plan: Discuss medication options, set expectations, obtain informed consent
• E-prescribe: First-line agent via EPCS after PDMP check

First-line medication choices:

• Modafinil (Provigil) or armodafinil (Nuvigil): Schedule IV, 200-250mg daily, fewer side effects than stimulants, good starting point
• Methylphenidate (Ritalin, Concerta): Schedule II, 20-60mg daily, divided doses
• Amphetamine salts (Adderall): Schedule II, 10-40mg daily, may need higher doses than ADHD

Follow-up schedule:

• Week 2-4: Dose adjustment based on response
• Monthly: During titration phase (typically 3-6 months)
• Quarterly: Once stable on effective dose

Medication monitoring checklist (each visit):

• Symptom improvement (sleep attacks, daytime function)
• Side effects (BP, heart rate, appetite, insomnia, anxiety)
• PDMP review (mandatory before each controlled Rx in most states)
• Medication adherence
• Functional outcomes (able to work, drive safely?)

Prior authorization survival:Most narcolepsy meds require PA. Have patients gather:

• Sleep study report
• Specialist referral/diagnosis
• Documentation of daytime sleepiness severity

Many platforms (like Klarity) have support staff to handle PA paperwork—if you’re going solo, budget 30-60 minutes per patient for this.

Addressing the Adderall shortage:Since mid-2022, stimulant shortages have disrupted narcolepsy care. Be prepared to:

• Quickly switch to alternative stimulants (methylphenidate if patient on amphetamine, vice versa)
• Use multiple pharmacies
• Consider wakefulness promoters as backup
• Counsel patients proactively about supply issues

Special Considerations: Sodium Oxybate, Cataplexy, and Complex Cases

Sodium oxybate (Xyrem/Xywav):

• Schedule III controlled substance with restricted distribution
• Requires REMS enrollment (both prescriber and patient)
• Single specialty pharmacy (provider coordinates shipment)
• Used for narcolepsy with cataplexy—very effective but logistically complex
• Consider co-managing with sleep specialist if prescribing

Managing cataplexy:

• Sudden muscle weakness triggered by emotion (laughter, surprise)
• Often requires additional medication beyond stimulants
• Options: Sodium oxybate, SSRIs/SNRIs (off-label), tricyclic antidepressants
• Psychiatrists comfortable prescribing antidepressants have advantage here

Off-label prescribing:Some narcolepsy treatment involves off-label use:

• SSRIs for cataplexy
• Clonidine for nighttime sleep regulation
• Combination therapy (stimulant + modafinil)

Document rationale clearly, obtain informed consent, and follow evidence-based guidelines.

Compliance Essentials: PDMP, Documentation, and Risk Management

Prescription Drug Monitoring Programs (PDMPs):

• Nearly all states mandate PDMP checks before prescribing controlled substances
• Many require checks every time you prescribe (not just initial)
• New York, for example, requires query for every controlled Rx
• Most state PDMPs are accessible online during your telehealth visit

Documentation requirements:Since telehealth must meet ‘standard of care equivalent to in-person,’ your notes should include:

• Patient identity verification
• Location confirmation (for licensure and emergency purposes)
• Telehealth consent
• Clinical assessment (symptoms, functional impairment)
• Rationale for medication choice and dose
• PDMP check documentation
• Informed consent for controlled substances
• Plan for monitoring

E-prescribing of controlled substances (EPCS):

• Required in many states (CA, NY, IL, and others)
• DEA requires two-factor authentication for EPCS
• Telehealth platforms should provide compliant e-prescribing tools
• Paper prescriptions for Schedule II are mostly obsolete

Malpractice considerations:

• Ensure your malpractice carrier covers telehealth and controlled-substance prescribing
• Following evidence-based guidelines protects you
• Platforms with standardized protocols reduce individual provider risk

State Telehealth Law Updates: What Changed Recently

California:

• AB 890 implementation ongoing; 104 NPs certified starting 2026
• Telehealth parity permanent (audio-video or audio-only for some services)
• No additional telehealth prescribing restrictions beyond federal

Texas:

• Telemedicine framework established 2017; no major recent changes
• NP scope limitations remain (no Schedule II outpatient prescribing)
• High demand due to worst mental health access in nation

Florida:

• SB 312 (2022) allowed telehealth Schedule III-V prescribing; Schedule II still restricted except for psychiatric disorders, inpatient, hospice
• PMHNP autonomy bill (HB 771) failed in 2023
• 7-day Schedule II limit for NPs remains

New York:

• NP independence made permanent in 2022 budget
• Telehealth parity laws strong
• I-STOP PDMP checks mandatory

Pennsylvania:

• No major scope of practice changes for NPs
• Collaborative agreement requirements stable
• Telehealth permitted with standard oversight

Illinois:

• Full practice authority established 2017
• Telehealth parity permanent (2021 law)
• Mental health reimbursement equity legislation proposed 2025

Joining a Telehealth Platform: What to Look For

Not all telehealth platforms are created equal, especially for controlled-substance prescribing. Here’s what matters:

Essential platform features:

• EPCS-enabled e-prescribing integrated into workflow
• PDMP access or integration
• Automated appointment scheduling and reminders (reduce no-shows)
• Prior authorization support staff
• Liability insurance coverage for telehealth
• State-by-state compliance protocols

Provider compensation models:

• Per-visit pay (typically $50-100 per follow-up)
• Revenue share on billings
• Guaranteed minimums vs. pure volume-based

Patient acquisition:The platform should deliver pre-qualified patients, not dump all marketing on you. Questions to ask:

• How do you match patients to providers?
• What’s the average time to first patient?
• Do providers control their schedules?
• What happens if a patient no-shows?

For narcolepsy specifically:

• Does the platform credential providers for narcolepsy treatment?
• Can you request sleep study documentation before accepting a patient?
• Is there support for complex cases (sodium oxybate prescribing, etc.)?

State licensing support:Managing multi-state licensure is time-consuming. Better platforms:

• Guide you through compact states and individual licensure
• Identify high-demand states worth adding
• Handle credential verification with insurers

Common Provider Questions About Narcolepsy Prescribing

Q: Can I diagnose narcolepsy via telehealth, or do I need to defer to a sleep specialist?

You can confirm and treat narcolepsy via telehealth, but you typically need objective testing (polysomnography + MSLT) performed by a sleep lab. Most psychiatrists review existing sleep study results rather than ordering initial workups. If a patient doesn’t have diagnosis confirmation, refer them to a sleep specialist first, then manage medication afterward.

Q: What if my state requires an in-person exam for controlled substances after the federal waiver ends?

Plan ahead. Options include: (1) Partnership with a local physician network for one-time in-person exams, (2) Require patients to see a local provider for initial exam before starting telehealth, (3) Restrict practice to states without in-person requirements. Monitor DEA rulemaking closely through 2025-2026.

Q: How do I handle prior authorizations efficiently?

Either hire a VA/admin assistant to handle PA paperwork, or join a platform that provides PA support. Keep template letters and common documentation (sleep study summaries, severity scales) ready to submit quickly. Some insurers have online PA portals that expedite the process.

Q: Can I prescribe narcolepsy meds for patients in multiple states?

Yes, but you need to be licensed in each patient’s state. Physicians and NPs are NOT covered by interstate compacts for prescribing (PSYPACT is psychologists-only). You’ll need individual state medical/nursing licenses. Some platforms help with multi-state credentialing.

Q: What’s the difference between managing narcolepsy and ADHD from a prescribing standpoint?

Clinically, narcolepsy often requires higher stimulant doses and different timing (to combat severe daytime sleepiness vs. focus issues). Narcolepsy patients may need stimulants plus additional agents for cataplexy. Prescribing-wise, the regulations are identical (both use Schedule II stimulants), but insurance is often easier for narcolepsy since it’s considered a medical condition with objective diagnosis.

Q: Should I treat narcolepsy patients if I don’t have specialized training in sleep medicine?

You don’t need to be a sleep specialist, but you should be comfortable with stimulant management, familiar with narcolepsy medications, and willing to coordinate care. Many psychiatrists manage narcolepsy successfully—it’s primarily medication management once diagnosis is confirmed. Consider co-managing complex cases with a sleep neurologist.

Q: How do reimbursement rates compare to typical psychiatric medication management?

Similar. Narcolepsy follow-ups bill the same E/M codes as other med checks (99213/99214). Some argue narcolepsy (ICD-10 G47.4x) might be processed under medical benefits rather than behavioral health, potentially avoiding mental health parity issues and deductibles in some plans.

Q: What happens if I can’t find a pharmacy with the prescribed stimulant in stock?

Have backup plans: alternative stimulant formulations, different manufacturers, or wakefulness promoters. Build relationships with multiple pharmacies. Counsel patients to call ahead before heading to pharmacy. The ongoing shortage makes flexibility essential.

Q: As an NP, should I pursue narcolepsy management if my state limits Schedule II prescribing?

Depends on your state. In Texas or Florida, you’ll need close MD collaboration or stick to modafinil (which you can prescribe). In Illinois or New York (once experienced), you can manage independently. Assess whether restrictions make narcolepsy management worthwhile for your practice, or focus on states where you have full authority.

Q: How do I market myself as a narcolepsy provider without spending thousands on advertising?

Join a platform that handles patient acquisition. If going solo, focus on:

• Listing in specialized directories (not just general psych, but ‘narcolepsy treatment’ specifically)
• Building referral relationships with sleep clinics and neurologists
• Content marketing (blog posts, videos answering patient questions)
• Local patient advocacy groups

But honestly, DIY marketing costs $3,000-5,000/month before you see ROI. Platform models that match qualified patients to you are far more efficient.

The Bottom Line: Is Narcolepsy Telehealth Worth It?

For psychiatrists: Absolutely. You have full prescriptive authority in nearly every state, high patient demand due to specialist shortages, and the opportunity for predictable long-term med management relationships. The compliance requirements (PDMP checks, monthly prescribing, e-prescribing) are manageable with the right systems.

For PMHNPs: It depends on your state. If you’re in Illinois, New York, or California (with experience), you can manage narcolepsy nearly identically to MDs. In Texas or Florida, the restrictions make it harder—you’ll need strong physician collaboration or should focus on other conditions.

The economics make sense: Rather than gambling thousands per month on marketing that might not work, platforms that deliver pre-qualified narcolepsy patients on a pay-per-appointment basis offer guaranteed ROI. You only pay when patients book, and you control your schedule entirely.

The clinical work is straightforward: After initial evaluation, most narcolepsy patients need brief (15-20 min) monthly or quarterly med checks. This is efficient, billable work that fits well into telehealth models.

The unmet need is real: With 160,000 Americans living with narcolepsy and ongoing medication shortages creating care disruptions, providers who understand this condition and can prescribe effectively have a genuine opportunity to improve patient lives while building sustainable practices.

If you’re ready to start treating narcolepsy patients via telehealth, focus on: (1) Understanding your state’s scope of practice and telehealth rules, (2) Setting up compliant e-prescribing and PDMP access, (3) Joining a platform that handles patient acquisition so you can focus on clinical care, and (4) Building systems for efficient med management visits.

Narcolepsy patients are out there, searching for providers who actually understand their condition and can prescribe their medications reliably. By mastering the regulatory landscape and working with the right platform, you can be one of those providers.

References and Sources

All regulatory and clinical information in this guide was verified using official government sources, peer-reviewed publications, and reputable healthcare news outlets. Below are the key sources cited, including publication dates for transparency:

1. Drug Enforcement Administration & HHS – Telehealth Flexibilities Extension (November 2024) – Official announcement extending controlled substance prescribing via telehealth through December 2025. Source: Axios reporting on DEA/HHS decision, November 18, 2024. www.axios.com

2. Texas Medical Board – Schedule II Delegation Rules – Official guidance on NP/PA prescribing limitations under physician delegation, confirming Schedule II restricted to hospital/hospice settings only. www.tmb.state.tx.us

3. California Board of Registered Nursing – AB 890 Implementation (Updated 2024) – Official state board explanation of 103/104 NP categories and timeline for independent practice. www.rn.ca.gov

4. Florida Statutes – Chapter 464 (Nurse Practice Act) (2021 compilation, current through 2024) – Primary legal text detailing 7-day Schedule II prescription limit for APRNs and psychiatric nurse exception. www.flsenate.gov

5. New York State Budget Amendment – NP Independence (April 2022) – Legal analysis of permanent NP practice authority after 3,600 hours, eliminating collaborative agreement requirement. Rivkin Radler law firm summary. www.rivkinrounds.com

6. 49 Pennsylvania Code §21.284 (Current through October 2025) – Official PA regulations specifying 30-day Schedule II and 90-day Schedule III-IV limits for CRNP prescribing. www.pacodeandbulletin.gov

7. Illinois Compiled Statutes – Nurse Practice Act (225 ILCS 65/65-43) (Effective January 2018) – Full Practice Authority provisions including consultation requirements for Schedule II narcotics and benzodiazepines. www.ilga.gov

8. KFF Health News – Narcolepsy Medication Shortages & Patient Impact (January 2024) – Investigative reporting on Adderall shortage impact on narcolepsy patients, including prevalence statistics (1 in 2,000). Published via MedicalXpress. medicalxpress.com

9. National Law Review – Florida Telemedicine Prescribing Law (SB 312) (April 2022) – Legal summary of 2022 Florida law lifting telehealth ban on Schedule III-V while maintaining Schedule II restrictions. Foley & Lardner LLP analysis. natlawreview.com

10. Mental Health America & Axios – State Workforce Rankings (August 2024) – Data on Texas ranking last nationally for mental health access and workforce availability. Axios San Antonio reporting. www.axios.com

11. Axios Chicago & RTI International – Mental Health Reimbursement Gap (March 2025) – Analysis showing private insurers pay mental health providers 22% less than other physicians. Illinois legislative context. www.axios.com

12. Clinical Advisor – Medicare NP Reimbursement (February 2012, confirmed current 2025) – Documentation of Medicare’s 85% reimbursement rate for nurse practitioner services. www.clinicaladvisor.com

13. Psychiatric Services Journal – Workforce Projections (2022, cited via Axios August 2023) – Peer-reviewed projection of 31,000 psychiatrist shortage by 2024 and 160 million Americans in mental health shortage areas. www.axios.com

All state statutes and regulations were verified against current official legal codes as of February 2026. Federal DEA policies reflect most recent published guidance available. Where implementation timelines are noted (e.g., California 104 NP certification in 2026), these are based on statutory language and official board communications.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,person%20doctor%27s%20visit%20for%20the
• https://natlawreview.com/article/new-florida-law-allows-telemedicine-prescribing-controlled-substances#:~:text=controlled%20substances%20via%20telemedicine%2C%20with,more%20on
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,drugs%2C%20such%20as
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,require%20a%20physician%20name%3B
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%E2%80%99s%202023%20state%20budget%2C,practice%20without%20a%20collaborative%20relationship
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=Please%20note%2C%20the%20law%20requires,certify%20104%20NPs%20until%202026
• https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation#:~:text=1.%20in%20a%20hospital%20facility,has%20elected%20to%20receive%20hospice
• https://www.flsenate.gov/Laws/Statutes/2021/Chapter464/All#:~:text=match%20at%20L1566%20limit%20the,455
• https://www.pacodeandbulletin.gov/Display/pacode?file=%2Fsecure%2Fpacode%2Fdata%2F049%2Fchapter21%2Fs21.284.html#:~:text=,may%20not%20delegate%20prescriptive%20authority